RT Journal Article
SR Electronic
T1 Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.07.01.450707
DO 10.1101/2021.07.01.450707
A1 Mandy Jongeneelen
A1 Krisztian Kaszas
A1 Daniel Veldman
A1 Jeroen Huizingh
A1 Remko van der Vlugt
A1 Theo Schouten
A1 David Zuijdgeest
A1 Taco Uil
A1 Griet van Roey
A1 Nuria Guimera
A1 Marjon Navis
A1 Rinke Bos
A1 Mathieu le Gars
A1 Jerald Sadoff
A1 Leacky Muchene
A1 Jarek Juraszek
A1 Johannes PM Langedijk
A1 Ronald Vogels
A1 Jerome Custers
A1 Hanneke Schuitemaker
A1 Boerries Brandenburg
YR 2021
UL http://biorxiv.org/content/early/2021/07/01/2021.07.01.450707.abstract
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and recently emerging variants with substitutions in the Spike protein have led to growing concerns over increased transmissibility and decreased vaccine coverage due to immune evasion. Here, sera from recipients of a single dose of our Ad26.COV2.S COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants of concern. All tested variants demonstrated susceptibility to Ad26.COV2.S-induced serum neutralization albeit mainly reduced as compared to the B.1 strain. Most pronounced reduction was observed for the B.1.351 (Beta; 3.6-fold) and P.1 (Gamma; 3.4-fold) variants that contain similar mutations in the receptor-binding domain (RBD) while only a 1.6-fold reduction was observed for the widely spreading B.1.617.2 (Delta) variant.Competing Interest StatementAll authors are employed by Janssen Vaccine & Prevention B.V., Janssen Pharmaceutical Companies of Johnson & Johnson.